Allergan is under pressure from activist shareholders and other investors to formulate a clear strategic plan and make more drastic changes to the company.
Botox Aesthetics, Botox Migraine, and Restasis will all face upcoming competition which could hamper sales growth.
Critical catalysts are approaching that could materially change whether the company makes more drastic changes or not. Expect important readouts from ubrogepant, abicipar, and rapastinel over the next 6-9 months.
No comments:
Post a Comment